CTOs on the Move

Tao Life Sciences

www.taolifesciences.com

 
TAO Life Sciences invests in and develops early stage medical innovations. Working closely with physicians and researchers from universities and companies, TAO Life Sciences takes new concepts and turns them into reality. TAO Life Sciences is building a pipeline of promising medical device and life science innovations that will impact global healthcare markets and make a significant difference in people's lives. TAO Life Sciences applies its expertise to develop prototypes, demonstrate clinical proof of concept, and secure financial exits for our innovations. We bring design engineering, scientific direction, and business and legal strategy to clinicians' and researchers' new design concepts. In doing ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edifice Health

Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health.

Rubedo Life Sciences

Rubedo Life Sciences is an anti-aging company based in the Silicon Valley, California.

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.